The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma

Toshi Ghosh, Wilson Gonsalves, Dragan Jevremovic, Angela Dispenzieri, David M Dingli, Michael M. Timm, William G. Morice, Prashant Kapoor, Taxiarchis Kourelis, Martha Lacy, Suzanne R. Hayman, Francis K. Buadi, Nelson Leung, Ronald S. Go, Yi Lin, Stephen J Russell, John A. Lust, Steven R. Zeldenrust, Rahma Warsame, Yi L. HwaRobert A. Kyle, Morie Gertz, S Vincent Rajkumar, Shaji K Kumar

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Prior studies have revealed that the presence of increasing number of polyclonal plasma cells (pPCs) in the bone marrow (BM) are associated with better outcomes in newly diagnosed multiple myeloma (MM) patients. This effect has not been studied in patients with MM at the time of disease relapse. We determined the prognostic value of depletion of pPCs in the BM by 7-color multiparameter flow cytometry in a series of 174 relapsing MM patients. The time to next therapy (TTNT) in those with <5% pPCs was 9.4 months versus 13.9 months in those with ≥5% pPCs (P =.0091). The median overall survival (OS) in those with <5% pPCs was 21.4 months, while the median OS was not reached in those patients with ≥5% pPCs (P =.019). Of the 109 patients with standard risk cytogenetics, the median OS of those with <5% pPCs was 28.4 months, while the median OS was not reached in those with ≥5% pPCs (P =.033). As such, <5% pPCs in the BM appears to have prognostic utility in identifying a subset of relapsing MM patients, even with standard-risk cytogenetics, who have a particularly adverse outcome.

Original languageEnglish (US)
Pages (from-to)E507-E512
JournalAmerican Journal of Hematology
Volume92
Issue number9
DOIs
StatePublished - Sep 1 2017

Fingerprint

Plasma Cells
Multiple Myeloma
Bone Marrow Cells
Survival
Bone Marrow
Cytogenetics
Flow Cytometry
Color
Recurrence

ASJC Scopus subject areas

  • Hematology

Cite this

The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. / Ghosh, Toshi; Gonsalves, Wilson; Jevremovic, Dragan; Dispenzieri, Angela; Dingli, David M; Timm, Michael M.; Morice, William G.; Kapoor, Prashant; Kourelis, Taxiarchis; Lacy, Martha; Hayman, Suzanne R.; Buadi, Francis K.; Leung, Nelson; Go, Ronald S.; Lin, Yi; Russell, Stephen J; Lust, John A.; Zeldenrust, Steven R.; Warsame, Rahma; Hwa, Yi L.; Kyle, Robert A.; Gertz, Morie; Rajkumar, S Vincent; Kumar, Shaji K.

In: American Journal of Hematology, Vol. 92, No. 9, 01.09.2017, p. E507-E512.

Research output: Contribution to journalArticle

Ghosh, Toshi ; Gonsalves, Wilson ; Jevremovic, Dragan ; Dispenzieri, Angela ; Dingli, David M ; Timm, Michael M. ; Morice, William G. ; Kapoor, Prashant ; Kourelis, Taxiarchis ; Lacy, Martha ; Hayman, Suzanne R. ; Buadi, Francis K. ; Leung, Nelson ; Go, Ronald S. ; Lin, Yi ; Russell, Stephen J ; Lust, John A. ; Zeldenrust, Steven R. ; Warsame, Rahma ; Hwa, Yi L. ; Kyle, Robert A. ; Gertz, Morie ; Rajkumar, S Vincent ; Kumar, Shaji K. / The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. In: American Journal of Hematology. 2017 ; Vol. 92, No. 9. pp. E507-E512.
@article{ac40be888d154b1e825bba7aa06e0981,
title = "The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma",
abstract = "Prior studies have revealed that the presence of increasing number of polyclonal plasma cells (pPCs) in the bone marrow (BM) are associated with better outcomes in newly diagnosed multiple myeloma (MM) patients. This effect has not been studied in patients with MM at the time of disease relapse. We determined the prognostic value of depletion of pPCs in the BM by 7-color multiparameter flow cytometry in a series of 174 relapsing MM patients. The time to next therapy (TTNT) in those with <5{\%} pPCs was 9.4 months versus 13.9 months in those with ≥5{\%} pPCs (P =.0091). The median overall survival (OS) in those with <5{\%} pPCs was 21.4 months, while the median OS was not reached in those patients with ≥5{\%} pPCs (P =.019). Of the 109 patients with standard risk cytogenetics, the median OS of those with <5{\%} pPCs was 28.4 months, while the median OS was not reached in those with ≥5{\%} pPCs (P =.033). As such, <5{\%} pPCs in the BM appears to have prognostic utility in identifying a subset of relapsing MM patients, even with standard-risk cytogenetics, who have a particularly adverse outcome.",
author = "Toshi Ghosh and Wilson Gonsalves and Dragan Jevremovic and Angela Dispenzieri and Dingli, {David M} and Timm, {Michael M.} and Morice, {William G.} and Prashant Kapoor and Taxiarchis Kourelis and Martha Lacy and Hayman, {Suzanne R.} and Buadi, {Francis K.} and Nelson Leung and Go, {Ronald S.} and Yi Lin and Russell, {Stephen J} and Lust, {John A.} and Zeldenrust, {Steven R.} and Rahma Warsame and Hwa, {Yi L.} and Kyle, {Robert A.} and Morie Gertz and Rajkumar, {S Vincent} and Kumar, {Shaji K}",
year = "2017",
month = "9",
day = "1",
doi = "10.1002/ajh.24807",
language = "English (US)",
volume = "92",
pages = "E507--E512",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma

AU - Ghosh, Toshi

AU - Gonsalves, Wilson

AU - Jevremovic, Dragan

AU - Dispenzieri, Angela

AU - Dingli, David M

AU - Timm, Michael M.

AU - Morice, William G.

AU - Kapoor, Prashant

AU - Kourelis, Taxiarchis

AU - Lacy, Martha

AU - Hayman, Suzanne R.

AU - Buadi, Francis K.

AU - Leung, Nelson

AU - Go, Ronald S.

AU - Lin, Yi

AU - Russell, Stephen J

AU - Lust, John A.

AU - Zeldenrust, Steven R.

AU - Warsame, Rahma

AU - Hwa, Yi L.

AU - Kyle, Robert A.

AU - Gertz, Morie

AU - Rajkumar, S Vincent

AU - Kumar, Shaji K

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Prior studies have revealed that the presence of increasing number of polyclonal plasma cells (pPCs) in the bone marrow (BM) are associated with better outcomes in newly diagnosed multiple myeloma (MM) patients. This effect has not been studied in patients with MM at the time of disease relapse. We determined the prognostic value of depletion of pPCs in the BM by 7-color multiparameter flow cytometry in a series of 174 relapsing MM patients. The time to next therapy (TTNT) in those with <5% pPCs was 9.4 months versus 13.9 months in those with ≥5% pPCs (P =.0091). The median overall survival (OS) in those with <5% pPCs was 21.4 months, while the median OS was not reached in those patients with ≥5% pPCs (P =.019). Of the 109 patients with standard risk cytogenetics, the median OS of those with <5% pPCs was 28.4 months, while the median OS was not reached in those with ≥5% pPCs (P =.033). As such, <5% pPCs in the BM appears to have prognostic utility in identifying a subset of relapsing MM patients, even with standard-risk cytogenetics, who have a particularly adverse outcome.

AB - Prior studies have revealed that the presence of increasing number of polyclonal plasma cells (pPCs) in the bone marrow (BM) are associated with better outcomes in newly diagnosed multiple myeloma (MM) patients. This effect has not been studied in patients with MM at the time of disease relapse. We determined the prognostic value of depletion of pPCs in the BM by 7-color multiparameter flow cytometry in a series of 174 relapsing MM patients. The time to next therapy (TTNT) in those with <5% pPCs was 9.4 months versus 13.9 months in those with ≥5% pPCs (P =.0091). The median overall survival (OS) in those with <5% pPCs was 21.4 months, while the median OS was not reached in those patients with ≥5% pPCs (P =.019). Of the 109 patients with standard risk cytogenetics, the median OS of those with <5% pPCs was 28.4 months, while the median OS was not reached in those with ≥5% pPCs (P =.033). As such, <5% pPCs in the BM appears to have prognostic utility in identifying a subset of relapsing MM patients, even with standard-risk cytogenetics, who have a particularly adverse outcome.

UR - http://www.scopus.com/inward/record.url?scp=85025079261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025079261&partnerID=8YFLogxK

U2 - 10.1002/ajh.24807

DO - 10.1002/ajh.24807

M3 - Article

C2 - 28568244

AN - SCOPUS:85025079261

VL - 92

SP - E507-E512

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 9

ER -